P06: UPDATED RESULTS FROM THE PHASE 1/2 MAJESTEC-1 STUDY OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA. (5th April 2022)

• Record Type: Journal Article
• Authors: Popat, R; Usmani, S; Garfall, A; van de Donk, N; Nahi, H; San-Miguel, J; Oriol, A; Nooka, A; Martin, T; Rosinol, L; Chari, A; Karlin, L; Benboubker, L; Mateos, M; Bahlis, N; Moreau, P; Besemer, B; Martínez-López, J; Sidana, S; Pei, L; Trancucci, D; Verona, R; Girgis, S; Olyslager, Y; Jaffe, M; Uhlar, C; Stephenson, T; Van Rampelbergh, R; Banerjee, A; Goldberg, J; Kobos, R; Krishnan, A;
• Is Part Of: HemaSphere. Volume 6(2022)Supplement 2
• Page Start: 14
• Page End: 14
• Publication Date: 2022-04-05
• Subjects: Hematology -- Periodicals; 616.15005
• DOI: 10.1097/01.HS9.0000829596.42296.29
• Languages: English
• ISSNs: 2572-9241